Compare AbCellera Biologics Inc (ABCL) vs Huntington Ingalls Industries Inc (HII) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

HII trades at $294.10, up 0.89% with a bullish technical signal supported by recent contract wins and strong earnings beats. The company maintains solid fundamentals with a 4.71% net margin and 12.2% ROE, while analyst consensus targets $384.50 representing 31% upside potential. Recent developments include a $418 million Navy contract and expansion in unmanned systems production.

HII presents a compelling investment case with consistent earnings outperformance, robust defense contracts, and attractive valuation metrics. Key risks include defense budget dependencies and execution challenges, but the company's $54 billion backlog and strategic positioning in naval shipbuilding support long-term growth prospects.